-
Something wrong with this record ?
Heterogeneity of molecular forms of dipeptidyl peptidase-IV and fibroblast activation protein in human glioblastomas
I. Matrasova, P. Busek, E. Balaziova, A. Sedo
Language English Country Czech Republic
Document type Journal Article
Grant support
NV15-31379A
MZ0
CEP Register
Digital library NLK
Full text - Article
NLK
Directory of Open Access Journals
from 2001
Free Medical Journals
from 1998
Medline Complete (EBSCOhost)
from 2007-06-01
ROAD: Directory of Open Access Scholarly Resources
from 2001
PubMed
28452380
DOI
10.5507/bp.2017.010
Knihovny.cz E-resources
- MeSH
- Dipeptidyl Peptidase 4 physiology MeSH
- Electrophoresis MeSH
- Enzyme-Linked Immunosorbent Assay MeSH
- Cell Fractionation MeSH
- Genetic Heterogeneity MeSH
- Glioblastoma enzymology MeSH
- Immunohistochemistry MeSH
- Isoelectric Focusing MeSH
- Humans MeSH
- Membrane Proteins physiology MeSH
- Brain enzymology pathology MeSH
- Tumor Cells, Cultured MeSH
- Serine Endopeptidases physiology MeSH
- Enzyme Stability MeSH
- Gelatinases physiology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
BACKGROUND AND AIMS: Proteolytic enzymes contribute to the progression of various cancers. We previously reported increased expression of the proline specific peptidases dipeptidyl peptidase-IV (DPP-IV) and its closest paralogue fibroblast activation protein (FAP) in human glioblastomas. Here we analyze the molecular heterogeneity of DPP-IV and FAP in glioblastomas. METHODS: ELISA, isoelectric focusing, 1D and 2D electrophoresis followed by WB or enzyme overlay assay were utilized to analyze DPP-IV and FAP isoforms. Cell fractionation using a Percoll gradient and deglycosylation with PNGase F were performed to analyze the possible basis of DPP-IV and FAP microheterogeneity. RESULTS: Molecular forms of DPP-IV with an estimated molecular weight of 140-160 kDa and a pI predominantly 5.8 were detected in human glioblastoma; in some tumors additional isoforms with a more acidic (3.5-5.5) as well as alkaline (8.1) pI were revealed. Using 2D electrophoresis, two to three molecular forms of FAP with an alkaline (7.0-8.5) pI and an estimated MW of 120-140 kDa were identified in glioblastoma tissues. In glioma cell lines in vitro, several isoforms of both enzymes were expressed, however the alkalic forms present in glioblastoma tissues were not detected. Removal of N-linked oligosaccharides decreased the estimated molecular weight of both enzymes; the overall pattern of molecular forms nevertheless remained unchanged. CONCLUSION: Several isoforms of DPP-IV and FAP are present in glioblastoma tissue. The absence of alkaline isoforms of both enzymes in glioma cell lines however suggests that isoforms from other, most likely stromal, cell types contribute to the overall pattern seen in glioblastoma tissues.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18025569
- 003
- CZ-PrNML
- 005
- 20180810085205.0
- 007
- ta
- 008
- 180711s2017 xr ad f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.5507/bp.2017.010 $2 doi
- 035 __
- $a (PubMed)28452380
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Matrasová, Ivana $u Institute of Biochemistry and Experimental Oncology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic $7 xx0212899
- 245 10
- $a Heterogeneity of molecular forms of dipeptidyl peptidase-IV and fibroblast activation protein in human glioblastomas / $c I. Matrasova, P. Busek, E. Balaziova, A. Sedo
- 520 9_
- $a BACKGROUND AND AIMS: Proteolytic enzymes contribute to the progression of various cancers. We previously reported increased expression of the proline specific peptidases dipeptidyl peptidase-IV (DPP-IV) and its closest paralogue fibroblast activation protein (FAP) in human glioblastomas. Here we analyze the molecular heterogeneity of DPP-IV and FAP in glioblastomas. METHODS: ELISA, isoelectric focusing, 1D and 2D electrophoresis followed by WB or enzyme overlay assay were utilized to analyze DPP-IV and FAP isoforms. Cell fractionation using a Percoll gradient and deglycosylation with PNGase F were performed to analyze the possible basis of DPP-IV and FAP microheterogeneity. RESULTS: Molecular forms of DPP-IV with an estimated molecular weight of 140-160 kDa and a pI predominantly 5.8 were detected in human glioblastoma; in some tumors additional isoforms with a more acidic (3.5-5.5) as well as alkaline (8.1) pI were revealed. Using 2D electrophoresis, two to three molecular forms of FAP with an alkaline (7.0-8.5) pI and an estimated MW of 120-140 kDa were identified in glioblastoma tissues. In glioma cell lines in vitro, several isoforms of both enzymes were expressed, however the alkalic forms present in glioblastoma tissues were not detected. Removal of N-linked oligosaccharides decreased the estimated molecular weight of both enzymes; the overall pattern of molecular forms nevertheless remained unchanged. CONCLUSION: Several isoforms of DPP-IV and FAP are present in glioblastoma tissue. The absence of alkaline isoforms of both enzymes in glioma cell lines however suggests that isoforms from other, most likely stromal, cell types contribute to the overall pattern seen in glioblastoma tissues.
- 650 _2
- $a mozek $x enzymologie $x patologie $7 D001921
- 650 _2
- $a frakcionace buněk $7 D002458
- 650 _2
- $a dipeptidylpeptidasa 4 $x fyziologie $7 D018819
- 650 _2
- $a elektroforéza $7 D004586
- 650 _2
- $a stabilita enzymů $7 D004795
- 650 _2
- $a ELISA $7 D004797
- 650 _2
- $a želatinasy $x fyziologie $7 D018093
- 650 _2
- $a genetická heterogenita $7 D018740
- 650 _2
- $a glioblastom $x enzymologie $7 D005909
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunohistochemie $7 D007150
- 650 _2
- $a isoelektrická fokusace $7 D007525
- 650 _2
- $a membránové proteiny $x fyziologie $7 D008565
- 650 _2
- $a serinové endopeptidasy $x fyziologie $7 D012697
- 650 _2
- $a nádorové buňky kultivované $7 D014407
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Bušek, Petr $u Institute of Biochemistry and Experimental Oncology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic $7 xx0094315
- 700 1_
- $a Balážiová, Eva $u Institute of Biochemistry and Experimental Oncology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic $7 xx0126036
- 700 1_
- $a Šedo, Aleksi, $u Institute of Biochemistry and Experimental Oncology, 1st Faculty of Medicine, Charles University in Prague, Prague , Czech Republic $d 1967- $7 jn20000605245
- 773 0_
- $w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czech Republic $x 1213-8118 $g Roč. 161, č. 3 (2017), s. 252-260
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28452380 $y Pubmed
- 910 __
- $a ABA008 $b A 1502 $c 958 $y 4 $z 0
- 990 __
- $a 20180711 $b ABA008
- 991 __
- $a 20180723095923 $b ABA008
- 999 __
- $a ok $b bmc $g 1324903 $s 1022491
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 161 $c 3 $d 252-260 $e 20170426 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
- GRA __
- $a NV15-31379A $p MZ0
- LZP __
- $b NLK118 $a Pubmed-20180711